Shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) traded up 51.66% after announcing the encouraging result of a Phase 3 trial evaluating its drug candidate ganaxolone
Biotechnology is considered to be the backbone of many industrial sectors and it makes a significant contribution to the well being of society. Every single
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.